Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01709734
Title A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
Acronym ARMOR2
Recruitment Terminated
Gender male
Phase Phase II
Variant Requirements No
Sponsors Tokai Pharmaceuticals
Indications
Therapies
Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.